Review examines metformin's role at the intersection of aging and longevity research

Published in Aging journal, this review examines metformin's emerging status as a potential longevity drug beyond its established role in diabetes treatment. Metformin has garnered significant attention in geroscience circles, with the ongoing TAME (Targeting Aging with Metformin) trial testing whether it can delay age-related diseases in non-diabetic older adults. The review likely synthesizes evidence on metformin's effects on fundamental aging hallmarks—including improved mitochondrial function, activation of AMPK (a cellular energy sensor), reduction in inflammation, and potential effects on cellular senescence. Observational studies have suggested metformin users may have lower rates of certain cancers and cardiovascular disease compared to users of other diabetes medications. However, the evidence remains mixed. While metformin is safe and inexpensive, its benefits in healthy aging individuals are still unproven. Some studies suggest it might actually impair adaptations to exercise in older adults, potentially limiting its utility. The practical takeaway: metformin remains a promising but unproven longevity intervention. Those without diabetes should await results from ongoing clinical trials rather than self-experimenting. For diabetics already taking metformin, the potential longevity benefits may be an additional bonus to glucose control.